

Related Companies | [] | ||||||||
Related Funds | [] | ||||||||
English | |||||||||
oda_MaterialEventDisclosureGeneralAbstract| |
| ||||||||
oda_UpdateAnnouncementFlag| |
| Hayır (No) | |||||||
oda_CorrectionAnnouncementFlag| |
| Hayır (No) | |||||||
oda_DateOfThePreviousNotificationAboutTheSameSubject| |
| - | |||||||
oda_DelayedAnnouncementFlag| |
| Hayır (No) | |||||||
oda_AnnouncementContentSection| |
| ||||||||
oda_ExplanationSection| |
| ||||||||
oda_ExplanationTextBlock| | Med Service Plus Company, authorized by the Kazakhstan Representative Office of our company, GEN İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN), has participated in the drug procurement tender organized by SK Pharmacy, the official institution of the Ministry of Health of the Republic of Kazakhstan. As a result of the aforementioned tender, our product 'Ilopera', containing the active ingredient Iloprost and manufactured at GEN's Production Facility in Ankara, has won its first tender in Kazakhstan. The agreement, under which the first drug shipment is projected to take place at the end of November 2026, will cover the year 2027, and its total contribution to GEN's sales is expected to be USD 838,620
In case of any discrepancy between the Turkish and English texts, the Turkish text shall prevail. | ||||||||
We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.